



## One Wales Medicines Process work programme July 2023

NB. In order of One Wales Medicines Assessment Group assessment/review date, most recent first.

\*Welsh Government will ratify all new OWMAG decisions made from 01/01/2023 onwards

Medicine	Indication	One Wales Medicines Assessment Group Date	Chief Executives/ AWMSG endorsement date	WG ratification date*	One Wales Interim Decision	Latest review meeting date	Review decision
Sorafenib	Maintenance treatment following allogeneic stem cell transplantation for acute myeloid leukaemia associated with a FLT3 ITD mutation	28/02/2022	31/03/2022	N/A	Supported	22/05/2023	Interim decision to continue for 3 years
Dostarlimab (Jemperli)	Locally advanced treatment-naïve stage II/III deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) rectal cancer	19/06/2023					
Mepolizumab	Treatment of chronic eosinophilic pneumonia	25/11/2019	23/12/2019	N/A	Not supported	19/06/2023	
Arsenic trioxide	Acute promyelocytic leukaemia - 1st line therapy in patients unsuitable for anthracycline-based therapy	26/09/2016	24/10/2016	N/A	Supported – partially superseded by NICE FAD 04/05/2018	10/07/2023	

**One Wales work programme  
July 2023 continued**

Medicine	Indication	One Wales Medicines Assessment Group Date	Chief Executives/ AWMSG endorsement date	WG ratification date*	One Wales Interim Decision	Latest review meeting date	Review decision
Azacitidine	Relapsed angio-immunoblastic T cell lymphoma (second and third line) - for patients that are not fit/suitable for intensification of therapy with a BEAM conditioned autograft	18/05/2020	29/06/2020	N/A	Supported	10/07/2023	
Rituximab	Treatment of pemphigus and pemphigoid disease in adults and children where third- or fourth-line treatments, including steroids and steroid sparing treatments have failed.	26/06/2017	20/07/2017	N/A	Supported Indication changed to 2nd and 4th line treatment following 2018 review. Pemphigus vulgaris superseded by AWMSG advice 14/09/2022	10/07/2023	
Rituximab	Treatment of myasthenia gravis in adults 1st line and for refractory disease 4 <sup>th</sup> line and later. (reassessment in March 2023 to consider change in pathway to first line and later use)	20/03/2023	19/04/2023	25/04/2023	Supported		

**One Wales work programme  
July 2023 continued**

Medicine	Indication	One Wales Medicines Assessment Group Date	Chief Executives/ AWMSG endorsement date	WG ratification date*	One Wales Interim Decision	Latest review meeting date	Review decision
Infliximab	Treatment of pulmonary sarcoidosis refractory to standard treatments and when there are no pharmacological alternatives	19/12/2022	03/03/2023	N/A	Supported		
Ustekinumab	Treatment of inflammatory bowel disease in children: ulcerative colitis following loss of response or non-response to anti-TNF and vedolizumab; Crohn's disease following loss of response or non-response to anti-TNF.	19/12/2022	03/03/2023	N/A	Supported		
Vedolizumab	Treatment of inflammatory bowel disease in children: ulcerative colitis following loss of response or non-response to anti-TNF treatment; Crohn's disease following loss of response or non-response to anti-TNF and ustekinumab.	19/12/2022	03/03/2023	N/A	Supported		
Infliximab	Treatment of Immune Checkpoint Inhibitor (ICI) induced grade 3-4 colitis, where symptoms have not responded to first line immunosuppression with corticosteroids	28/11/2022	2/02/2023	N/A	Supported		

**One Wales work programme  
July 2023 continued**

Medicine	Indication	One Wales Medicines Assessment Group Date	Chief Executives/ AWMSG endorsement date	WG ratification date*	One Wales Interim Decision	Latest review meeting date	Review decision
Vedolizumab	Treatment of Immune Checkpoint Inhibitor (ICI) induced grade 3-4 colitis, where symptoms have not responded to first line immunosuppression with corticosteroids and/or other immunosuppressant drugs like infliximab	28/11/2022	2/02/2023	N/A	Supported		
Bevacizumab	At a dose of 7.5 mg/kg in combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer	24/06/2019 (re-assessment)	18/07/2019	N/A	Supported	24/10/2022	Interim decision to continue for 12 months
Rituximab + bendamustine	Treatment of indolent lymphomas, first line and relapsed. To include follicular lymphoma, Waldenström's and marginal zone lymphoma	27/03/2017	28/04/2017	N/A	Supported	24/10/2022	Interim decision to continue for 12 months
Rituximab + bendamustine	Treatment of mantle cell lymphoma, first line and relapsed	27/03/2017	28/04/2017	N/A	Supported	24/10/2022	Interim decision to continue for 12 months

**One Wales work programme  
July 2023 continued**

<b>Medicine</b>	<b>Indication</b>	<b>One Wales Medicines Assessment Group Date</b>	<b>Chief Executives/ AWMSG endorsement date</b>	<b>WG ratification date*</b>	<b>One Wales Interim Decision</b>	<b>Latest review meeting date</b>	<b>Review decision</b>
Abiraterone (Zytiga)	Treatment of non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer.	26/09/2022	04/11/2022	N/A	Supported		
Rituximab	Treatment of progressive fibrotic interstitial lung disease (not idiopathic pulmonary fibrosis) related to underlying connective tissue disease or idiopathic fibrotic non-specific interstitial pneumonia which has not responded to first line immunosuppressive therapy with either azathioprine or mycophenolate mofetil	29/04/2019	22/08/2019	N/A	Supported	29/11/2021	Interim decision to continue for 2 years
Vonicog alfa (Veyvondi)	On-demand treatment of non-surgical and surgical (elective and emergency) bleeding episodes in children aged up to 17 years with severe von Willebrand disease	26/09/2022	04/11/2022	N/A	Supported		
Adalimumab	Treatment of paediatric patients with severe refractory non-infectious uveitis	22/08/2016	11/10/2016	N/A	Supported - partially superseded by AWMSG advice 08/12/2017	26/07/2021	Interim decision to continue for 2 years

**One Wales work programme  
July 2023 continued**